Zynerba Pharmaceuticals (NASDAQ:ZYNE) Given Daily Media Sentiment Score of 0.24

Share

Where the relative strength index (RSI) is a technical momentum indicator that compares the magnitude of recent gains to recent losses in an attempt to determine excess buying & selling conditions of an asset, it is one of the most popular technical indicators, computed on the basis of the speed and direction of a stock's price movement. HC Wainwright's target price indicates a potential upside of 4.95% from the stock's current price.

A number of other brokerages have also weighed in on ZYNE. Zacks Investment Research cut Zynerba Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Tuesday, May 30th. Jefferies Group LLC reaffirmed a "buy" rating and issued a $32.00 price target on shares of Zynerba Pharmaceuticals in a report on Thursday, May 25th. The rating was initiated by Oppenheimer with "Outperform" on Tuesday, September 8.

Shares of Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) plummets -54.18% in Monday's pre-session trade.

Among 18 analysts covering ElringKlinger (ETR:ZIL2), 5 have Buy rating, 6 Sell and 7 Hold. The company has market cap of $85.69 million. INFN's distance from 20 day simple moving average is -17.43% and distance from 50-Day simple moving average is -14.15%.

Zynerba Pharmaceuticals, Inc. (ZYNE) stock exposed a turn of -4.80% in most recent week and accomplished -12.08% performance over the last one month. However a year ago for the same quarter the company has reported $-0.67 EPS. On average, equities analysts predict that Zynerba Pharmaceuticals will post ($2.46) EPS for the current year.

TRADEMARK VIOLATION NOTICE: "Zynerba Pharmaceuticals, Inc". If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of US and global trademark & copyright law. The legal version of this report can be viewed at https://weekherald.com/2017/08/08/zynerba-pharmaceuticals-nasdaqzyne-getting-somewhat-negative-press-coverage-analysis-shows.html. In terms of the mechanics underlying that movement, traders will want to note that the stock is trading on a float of 25.85% with $10.57 Million sitting short, betting on future declines. The shares were acquired at an average price of $19.82 per share, with a total value of $103,064.00. The purchase was disclosed in a filing with the SEC, which is available through this link. Following the completion of the transaction, the chairman now owns 336,012 shares in the company, valued at $6,619,436.40.

The stock of Zynerba Pharmaceuticals Incorporated (NASDAQ:ZYNE) registered an increase of 0.02% in short interest.

Shares of Zynerba Pharmaceuticals (ZYNE) traded down 3.90% during trading on Tuesday, hitting $6.41.

The shares performance of ZYNE was -62.25% for the last one month and -52.70% in the previous week, whereas year to date performance was calculated -57.22%.

In other Zynerba Pharmaceuticals news, Chairman Armando Anido purchased 5,000 shares of the firm's stock in a transaction that occurred on Monday, May 15th. Sphera Funds Management LTD. bought a new stake in Zynerba Pharmaceuticals during the first quarter worth about $2,010,000. The firm's institutional ownership remained 95.90% while insider ownership included 2.30%.

Zynerba Pharmaceuticals, Inc. engages in the research and development of drugs.

ZYN002, a synthetic transdermal cannabidiol gel, failed to demonstrate a statistically significant reduction of focal seizures with either the high or low dose compared to placebo. Its clinical programs include synthetic cannabinoid therapeutics and patch and gel for transdermal delivery.

Share